Trial
NCT00584740
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Crohn's Disease
Intervention
AIN457
Why stopped
The study was terminated prematurely after futility criterion was met at planned interim analysis of 41 patients.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-31